HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Incidence of post-ERCP pancreatitis from direct pancreatic juice collection in hereditary pancreatitis and familial pancreatic cancer before and after the introduction of prophylactic pancreatic stents and rectal diclofenac.

AbstractOBJECTIVES:
Individuals from hereditary pancreatitis (HP) and familial pancreatic cancer (FPC) kindreds are at increased risk of developing pancreatic cancer. Premalignant molecular changes may be detected in pancreatic juice collected by endoscopic retrograde cholangiopancreatography (ERCP). The objective was to determine the risk of post-ERCP pancreatitis (PEP).
METHODS:
A prospective study (1999-2013) was undertaken of 80 ERCPs (24 in HP and 56 in FPC) from 60 individuals and the impact of PEP prophylaxis using a self-expelling pancreatic stent and 50 mg diclofenac per rectum from 2008.
RESULTS:
There was no PEP in the HP cohort and 13 (23.2%) PEP from 56 procedures in the FPC cohort (P = 0.0077). Up to 2008 PEP had occurred in 7 (43.8%) of 16 procedures in FPC individuals versus none of 18 procedures in HP individuals (P = 0.0021). After the introduction of prophylaxis, the incidence of PEP fell to 6 (15.0%) of 40 procedures in FPC individuals (P = 0.0347).The odds ratio (95% confidence interval) was 0.23 (0.06-0.84) in favor of prophylaxis (0.035).
CONCLUSIONS:
Individuals with HP are at minimal risk for PEP. Although the risk of PEP in individuals with FPC can be reduced by using prophylactic self-expelling stents and diclofenac, it remains too high for routine screening.
AuthorsJames A Nicholson, William Greenhalf, Richard Jackson, Trevor F Cox, Jane V Butler, Thomas Hanna, Sara Harrison, Christopher J Grocock, Christopher M Halloran, Nathan R Howes, Michael G Raraty, Paula Ghaneh, Marianne Johnstone, Sanchoy Sarkar, Howard L Smart, Jonathan C Evans, Guruprasad P Aithal, Robert Sutton, John P Neoptolemos, Martin G Lombard
JournalPancreas (Pancreas) Vol. 44 Issue 2 Pg. 260-5 (Mar 2015) ISSN: 1536-4828 [Electronic] United States
PMID25438071 (Publication Type: Comparative Study, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Biomarkers, Tumor
  • Diclofenac
Topics
  • Administration, Rectal
  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal (administration & dosage)
  • Biomarkers, Tumor (genetics)
  • Cholangiopancreatography, Endoscopic Retrograde (adverse effects)
  • Diclofenac (administration & dosage)
  • Female
  • Genetic Testing
  • Great Britain (epidemiology)
  • Humans
  • Incidence
  • Logistic Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Odds Ratio
  • Pancreatic Juice (chemistry)
  • Pancreatic Neoplasms (diagnosis, genetics)
  • Pancreatitis (diagnosis, epidemiology, prevention & control)
  • Pancreatitis, Chronic (diagnosis, genetics)
  • Predictive Value of Tests
  • Prospective Studies
  • Registries
  • Risk Assessment
  • Risk Factors
  • Stents
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: